Andy Siu on Yu, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 27
- 7 carriers
- Office
- 1
Offices
1 location
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
27 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yu’s office at (408) 286-3222 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
27 of 27 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G79122 · Current
Licensed to practise in California · since 1994 · expires 2028-02-29 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Forest Surgery Center LPAmbulatory Surgery Center · San Jose, CAOwner · accredited by JCAccreditation Renewed1 inspection, 1 with deficiencies · last 2012-09-18: Requirements Met
- Silicon Valley Surgery Center, LPAmbulatory Surgery Center · Campbell, CA5.83% owner since 2013 · accredited by AAAHCAccreditation Renewed4 inspections, 1 with deficiencies · last 2024-09-16
- Silicon Valley Surgery Center, LP - BascomAmbulatory Surgery Center · Campbell, CA5.83% owner since 2013 · accredited by AAAHCAccreditation RenewedNo inspections published
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 9.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$72,415
Medicare paid this office $72,415 for 261 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 120 | $16,257 | $96 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 89 | $15,762 | $177 |
| New patient visit (45+ min) | 123 | $12,710 | $103 |
| Biopsy of large bowel using a flexible endoscope | 158 | $12,638 | $79 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 99 | $6,260 | $60 |
See all 7 services
| Return visit (30+ min) | 120 | $16,257 | $96 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 89 | $15,762 | $177 |
| New patient visit (45+ min) | 123 | $12,710 | $103 |
| Biopsy of large bowel using a flexible endoscope | 158 | $12,638 | $79 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 99 | $6,260 | $60 |
| Long return visit (40+ min) | 18 | $3,480 | $145 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 18 | $2,450 | $136 |
Procedures Medicare counted
| Colonoscopy | 245 | More than 96% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 101 | More than 77% of doctors who do this |
Who their Medicare patients are
261 Original Medicare patients in 2024. Average age 72 · Women 52% · Health risk score 0.66. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 61% · Diabetes 27% · Coronary heart disease 19% · Chronic kidney disease 12% · Cancer 11% · Atrial fibrillation 7% · COPD 5% · Stroke 5%.
The office billed $477,590, Medicare allowed $108,604 and paid $72,415; for 713 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 261 | 713 | 72 | 0.66 | $477,590 | $72,415 |
| 2023 | 267 | 653 | 72 | 0.60 | $427,780 | $72,752 |
| 2022 | 287 | 681 | 72 | 0.61 | $424,325 | $77,953 |
| 2021 | 244 | 665 | 72 | 0.68 | $406,910 | $79,854 |
| 2020 | 174 | 425 | 72 | 0.77 | $269,605 | $43,496 |
| 2019 | 223 | 569 | 72 | 0.69 | $362,775 | $59,532 |
| 2018 | 230 | 636 | 72 | 0.85 | $416,250 | $72,818 |
| 2017 | 230 | 626 | 72 | 0.87 | $413,385 | $68,159 |
| 2016 | 228 | 558 | 72 | 0.84 | $341,760 | $60,840 |
| 2015 | 271 | 679 | 73 | 0.99 | $400,090 | $81,150 |
| 2014 | 381 | 970 | 75 | 0.97 | $574,019 | $118,356 |
| 2013 | 558 | 1,297 | 75 | 1.03 | $715,508 | $163,932 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 112 | $16,112 | $103 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 69 | $13,162 | $185 |
| Biopsy of large bowel using a flexible endoscope | 141 | $12,796 | $90 |
| New patient visit (45+ min) | 106 | $12,027 | $113 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 97 | $6,675 | $67 |
| Long return visit (40+ min) | 27 | $5,614 | $160 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 13 | $1,931 | $149 |
2022: 7 services
| New patient visit (45+ min) | 152 | $18,289 | $120 |
| Return visit (30+ min) | 116 | $17,422 | $107 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 81 | $16,463 | $201 |
| Biopsy of large bowel using a flexible endoscope | 131 | $10,691 | $80 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 79 | $5,440 | $66 |
| Long return visit (40+ min) | 22 | $4,248 | $157 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 11 | $1,697 | $141 |
2021: 7 services
| Return visit (30+ min) | 106 | $17,093 | $108 |
| New patient visit (45+ min) | 128 | $15,746 | $123 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 67 | $14,610 | $215 |
| Biopsy of large bowel using a flexible endoscope | 118 | $10,823 | $91 |
| Long return visit (40+ min) | 35 | $8,662 | $163 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 90 | $6,218 | $67 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 18 | $2,689 | $149 |
2020: 6 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $9,659 | $186 |
| New patient visit (45+ min) | 72 | $7,995 | $111 |
| Return visit (30+ min) | 64 | $7,441 | $85 |
| Biopsy of large bowel using a flexible endoscope | 78 | $5,106 | $65 |
| Long return visit (40+ min) | 35 | $4,549 | $108 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 51 | $3,721 | $65 |
2019: 8 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | $11,784 | $184 |
| Long return visit (40+ min) | 58 | $10,424 | $121 |
| New patient visit (45+ min) | 91 | $9,605 | $106 |
| Return visit (30+ min) | 68 | $7,621 | $85 |
| Biopsy of large bowel using a flexible endoscope | 98 | $6,812 | $69 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 80 | $5,640 | $67 |
| Control of bleeding of upper large bowel using a flexible endoscope | 14 | $3,004 | $215 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 12 | $1,682 | $129 |
2018: 8 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 77 | $14,678 | $188 |
| New patient visit (45+ min) | 109 | $13,619 | $125 |
| Long return visit (40+ min) | 45 | $8,756 | $129 |
| Return visit (30+ min) | 75 | $7,944 | $87 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 88 | $7,420 | $76 |
| Biopsy of large bowel using a flexible endoscope | 105 | $6,715 | $63 |
| Control of bleeding of upper large bowel using a flexible endoscope | 18 | $4,306 | $239 |
| New patient visit (60+ min) | 13 | $2,412 | $186 |
2017: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 75 | $13,330 | $173 |
| Return visit (30+ min) | 94 | $11,458 | $90 |
| New patient visit (45+ min) | 91 | $11,101 | $122 |
| Biopsy of large bowel using a flexible endoscope | 111 | $8,901 | $78 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 87 | $7,191 | $73 |
| Control of bleeding of upper large bowel using a flexible endoscope | 18 | $4,619 | $231 |
| Long return visit (40+ min) | 30 | $4,467 | $121 |
| New patient visit (60+ min) | 12 | $2,139 | $178 |
| Injection beneath lining of large bowel using a flexible endoscope | 14 | $723 | $52 |
2016: 7 services
| New patient visit (45+ min) | 90 | $11,075 | $123 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 58 | $10,562 | $182 |
| Return visit (30+ min) | 89 | $10,385 | $87 |
| Biopsy of large bowel using a flexible endoscope | 89 | $7,809 | $87 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 75 | $6,280 | $78 |
| Control of bleeding of upper large bowel using a flexible endoscope | 16 | $3,828 | $239 |
| New patient visit (30+ min) | 26 | $1,787 | $69 |
2015: 9 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 82 | $16,274 | $198 |
| Return visit (30+ min) | 112 | $14,993 | $95 |
| Biopsy of large bowel using a flexible endoscope | 112 | $11,301 | $101 |
| New patient visit (45+ min) | 69 | $9,695 | $141 |
| Control of bleeding of upper large bowel using a flexible endoscope | 30 | $8,772 | $292 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 84 | $7,644 | $89 |
| New patient visit (30+ min) | 63 | $5,287 | $84 |
| Short return visit (20+ min) | 21 | $1,448 | $58 |
| Injection beneath lining of large bowel using a flexible endoscope | 18 | $465 | $26 |
2014: 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 109 | $23,974 | $214 |
| Biopsy of large bowel using a flexible endoscope | 154 | $18,507 | $115 |
| Return visit (30+ min) | 140 | $18,430 | $95 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 138 | $13,469 | $90 |
| New patient visit (45+ min) | 85 | $12,305 | $145 |
| Control of bleeding of upper large bowel using a flexible endoscope | 34 | $10,252 | $293 |
| New patient visit (30+ min) | 73 | $6,623 | $91 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 20 | $4,360 | $218 |
| Short return visit (20+ min) | 51 | $3,563 | $64 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 11 | $1,329 | $121 |
| Injection beneath lining of large bowel using a flexible endoscope | 25 | $876 | $34 |
2013: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 126 | $27,157 | $209 |
| Return visit (30+ min) | 207 | $25,934 | $95 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 191 | $21,833 | $107 |
| Biopsy of large bowel using a flexible endoscope | 167 | $21,161 | $124 |
| New patient visit (45+ min) | 118 | $17,338 | $147 |
| Control of bleeding of upper large bowel using a flexible endoscope | 54 | $16,455 | $294 |
| New patient visit (30+ min) | 150 | $13,056 | $87 |
| Short return visit (20+ min) | 65 | $4,905 | $65 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 20 | $4,834 | $242 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 14 | $3,390 | $242 |
| Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | 11 | $1,335 | $121 |
| Injection beneath lining of large bowel using a flexible endoscope | 17 | $475 | $26 |
Drugs they prescribed that Part D paid
$309,211
Pharmacies billed $309,211 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 931) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
673 generic and 258 brand-name prescriptions · $309,211 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 162 | $241,447 | $1,490 |
| Sod Sulf-Potass Sulf-Mag Sulf | 178 | $12,128 | $68 |
| Mesalamine Er | 18 | $9,580 | $532 |
| Entecavir | 50 | $6,070 | $121 |
| Lamivudine Hbv | 14 | $5,663 | $405 |
See all 12 drugs
| Vemlidy | 162 | $241,447 | $1,490 |
| Sod Sulf-Potass Sulf-Mag Sulf | 178 | $12,128 | $68 |
| Mesalamine Er | 18 | $9,580 | $532 |
| Entecavir | 50 | $6,070 | $121 |
| Lamivudine Hbv | 14 | $5,663 | $405 |
| Mesalamine | 15 | $4,659 | $311 |
| Ursodiol | 12 | $2,688 | $224 |
| Famotidine | 178 | $2,026 | $11 |
| Tenofovir Disoproxil | 17 | $1,531 | $90 |
| Omeprazole | 152 | $1,006 | $7 |
| Peg 3350-Electrolyte | 28 | $541 | $19 |
| Hydrocortisone | 17 | $495 | $29 |
Year by year
| 2024 | 931 | 318 | 0% (0) | 28% | $309,211 |
| 2023 | 885 | 292 | 0% (0) | 36% | $337,845 |
| 2022 | 857 | 292 | 0% (0) | 43% | $320,923 |
| 2021 | 781 | 235 | 0% (0) | 42% | $282,965 |
| 2020 | 622 | 187 | None | 49% | $281,086 |
| 2019 | 653 | 207 | 0% (0) | None | $267,339 |
| 2018 | 704 | 228 | None | 53% | $299,899 |
| 2017 | 813 | 259 | 0% (0) | 53% | $329,107 |
| 2016 | 670 | 244 | 0% (0) | 54% | $388,207 |
| 2015 | 771 | 262 | 0% (0) | 52% | $474,424 |
| 2014 | 1,034 | 315 | None | 50% | $1,154,684 |
| 2013 | 1,137 | 386 | None | None | $331,501 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Vemlidy | 181 | $273,060 | $1,509 |
| Sod Sulf-Potass Sulf-Mag Sulf | 119 | $9,515 | $80 |
| Mesalamine Er | 15 | $9,399 | $627 |
| Mesalamine | 13 | $5,708 | $439 |
| Entecavir | 39 | $4,786 | $123 |
| Ursodiol | 12 | $3,598 | $300 |
| Lubiprostone | 13 | $3,107 | $239 |
| Famotidine | 208 | $3,054 | $15 |
| Clenpiq | 14 | $2,456 | $175 |
| Omeprazole | 109 | $1,038 | $10 |
| Peg 3350-Electrolyte | 47 | $1,020 | $22 |
| Paxlovid (Eua) | 11 | $11 | $1 |
2022: 12 drugs
| Vemlidy | 171 | $238,514 | $1,395 |
| Mesalamine Er | 20 | $13,618 | $681 |
| Mesalamine | 17 | $12,946 | $762 |
| Clenpiq | 71 | $11,774 | $166 |
| Entecavir | 35 | $9,755 | $279 |
| Suprep | 60 | $6,996 | $117 |
| Ursodiol | 18 | $3,772 | $210 |
| Famotidine | 179 | $2,377 | $13 |
| Peg 3350-Electrolyte | 55 | $1,048 | $19 |
| Omeprazole | 118 | $919 | $8 |
| Sod Sulf-Potass Sulf-Mag Sulf | 11 | $887 | $81 |
| Pantoprazole | 18 | $188 | $10 |
2021: 13 drugs
| Vemlidy | 166 | $212,792 | $1,282 |
| Mesalamine Er | 19 | $12,407 | $653 |
| Entecavir | 15 | $11,345 | $756 |
| Mesalamine | 15 | $9,983 | $666 |
| Clenpiq | 57 | $9,017 | $158 |
| Suprep | 45 | $4,985 | $111 |
| Ursodiol | 16 | $3,692 | $231 |
| Famotidine | 133 | $1,474 | $11 |
| Omeprazole | 119 | $913 | $8 |
| Peg 3350-Electrolyte | 36 | $663 | $18 |
| Esomeprazole Magnesium | 21 | $429 | $20 |
| Pantoprazole | 25 | $342 | $14 |
| Proctosol-Hc | 11 | $277 | $25 |
2020: 13 drugs
| Vemlidy | 148 | $198,997 | $1,345 |
| Entecavir | 21 | $17,757 | $846 |
| Mesalamine | 17 | $10,684 | $628 |
| Suprep | 90 | $9,352 | $104 |
| Lamivudine Hbv | 11 | $7,392 | $672 |
| Apriso | 12 | $6,060 | $505 |
| Ursodiol | 12 | $1,110 | $92 |
| Omeprazole | 102 | $706 | $7 |
| Famotidine | 61 | $399 | $7 |
| Esomeprazole Magnesium | 20 | $359 | $18 |
| Pantoprazole | 13 | $348 | $27 |
| Lansoprazole | 17 | $310 | $18 |
| Peg 3350-Electrolyte | 14 | $224 | $16 |
2019: 13 drugs
| Vemlidy | 164 | $206,444 | $1,259 |
| Entecavir | 23 | $12,295 | $535 |
| Apriso | 15 | $10,290 | $686 |
| Suprep | 101 | $10,029 | $99 |
| Mesalamine | 12 | $5,749 | $479 |
| Lamivudine Hbv | 13 | $4,315 | $332 |
| Tenofovir Disoproxil | 17 | $1,527 | $90 |
| Pantoprazole | 37 | $681 | $18 |
| Lansoprazole | 35 | $671 | $19 |
| Omeprazole | 48 | $555 | $12 |
| Esomeprazole Magnesium | 17 | $443 | $26 |
| Peg 3350-Electrolyte | 21 | $435 | $21 |
| Famotidine | 66 | $312 | $5 |
2018: 15 drugs
| Vemlidy | 194 | $216,849 | $1,118 |
| Entecavir | 20 | $17,550 | $878 |
| Tenofovir Disoproxil | 30 | $16,593 | $553 |
| Apriso | 13 | $8,800 | $677 |
| Suprep | 90 | $8,476 | $94 |
| Lamivudine Hbv | 25 | $6,021 | $241 |
| Mesalamine | 12 | $5,507 | $459 |
| Peg 3350-Electrolyte | 46 | $854 | $19 |
| Lansoprazole | 27 | $709 | $26 |
| Omeprazole | 43 | $600 | $14 |
| Esomeprazole Magnesium | 16 | $534 | $33 |
| Proctozone-Hc | 12 | $466 | $39 |
| Pantoprazole | 37 | $461 | $12 |
| Gavilyte-N | 15 | $302 | $20 |
| Famotidine | 33 | $121 | $4 |
2017: 15 drugs
| Vemlidy | 144 | $152,357 | $1,058 |
| Viread | 64 | $70,693 | $1,105 |
| Entecavir | 34 | $31,700 | $932 |
| Apriso | 18 | $10,225 | $568 |
| Suprep | 102 | $8,968 | $88 |
| Mesalamine | 14 | $6,755 | $482 |
| Lamivudine Hbv | 19 | $6,454 | $340 |
| Lamivudine | 13 | $2,644 | $203 |
| Lansoprazole | 66 | $2,345 | $36 |
| Esomeprazole Magnesium | 23 | $1,534 | $67 |
| Peg 3350-Electrolyte | 51 | $874 | $17 |
| Pantoprazole | 106 | $869 | $8 |
| Gavilyte-N | 31 | $581 | $19 |
| Omeprazole | 24 | $140 | $6 |
| Famotidine | 12 | $30 | $3 |
2016: 14 drugs
| Viread | 122 | $131,210 | $1,075 |
| Entecavir | 47 | $36,679 | $780 |
| Truvada | 12 | $17,540 | $1,462 |
| Baraclude | 12 | $15,538 | $1,295 |
| Nexium | 24 | $9,638 | $402 |
| Lamivudine Hbv | 11 | $5,117 | $465 |
| Suprep | 49 | $4,036 | $82 |
| Apriso | 12 | $3,016 | $251 |
| Lansoprazole | 55 | $1,751 | $32 |
| Peg 3350-Electrolyte | 71 | $1,187 | $17 |
| Gavilyte-N | 29 | $477 | $16 |
| Pantoprazole | 63 | $358 | $6 |
| Trilyte With Flavor Packets | 11 | $171 | $16 |
| Omeprazole | 24 | $155 | $6 |
2015: 18 drugs
| Viread | 129 | $144,164 | $1,118 |
| Entecavir | 51 | $45,320 | $889 |
| Baraclude | 13 | $16,354 | $1,258 |
| Truvada | 12 | $16,293 | $1,358 |
| Nexium | 42 | $13,241 | $315 |
| Lamivudine Hbv | 19 | $8,023 | $422 |
| Ursodiol | 16 | $5,677 | $355 |
| Lansoprazole | 81 | $3,621 | $45 |
| Moviprep | 23 | $1,852 | $81 |
| Suprep | 16 | $1,287 | $80 |
| Peg 3350-Electrolyte | 65 | $1,231 | $19 |
| Gavilyte-N | 44 | $891 | $20 |
| Trilyte With Flavor Packets | 28 | $587 | $21 |
| Pantoprazole | 42 | $299 | $7 |
| Omeprazole | 23 | $171 | $7 |
| Peg-3350 and Electrolytes | 12 | $161 | $13 |
| Famotidine | 16 | $111 | $7 |
| Amoxicillin | 11 | $70 | $6 |
2014: 23 drugs
| Sovaldi | 15 | $486,517 | $32,434 |
| Olysio | 13 | $338,028 | $26,002 |
| Viread | 111 | $118,375 | $1,066 |
| Baraclude | 78 | $96,406 | $1,236 |
| Nexium | 81 | $22,451 | $277 |
| Entecavir | 17 | $16,375 | $963 |
| Truvada | 12 | $15,774 | $1,314 |
| Adefovir Dipivoxil | 12 | $11,062 | $922 |
| Lansoprazole | 130 | $5,904 | $45 |
| Epivir Hbv | 12 | $5,392 | $449 |
| Delzicol | 11 | $4,901 | $446 |
| Ursodiol | 24 | $3,909 | $163 |
| Dexilant | 11 | $3,839 | $349 |
| Moviprep | 27 | $2,167 | $80 |
| Peg-3350 | 85 | $1,523 | $18 |
| Gavilyte-N | 53 | $1,046 | $20 |
| Clarithromycin | 16 | $914 | $57 |
| Trilyte With Flavor Packets | 36 | $680 | $19 |
| Omeprazole | 45 | $407 | $9 |
| Pantoprazole | 42 | $382 | $9 |
| Famotidine | 34 | $240 | $7 |
| Amoxicillin | 21 | $133 | $6 |
| Propranolol | 14 | $76 | $5 |
2013: 18 drugs
| Baraclude | 123 | $145,620 | $1,184 |
| Viread | 94 | $86,166 | $917 |
| Nexium | 87 | $20,811 | $239 |
| Truvada | 12 | $15,038 | $1,253 |
| Epivir Hbv | 20 | $10,749 | $537 |
| Lansoprazole | 109 | $6,465 | $59 |
| Ursodiol | 31 | $4,013 | $129 |
| Peg-3350 With Flavor Packs | 101 | $2,039 | $20 |
| Trilyte With Flavor Packets | 85 | $1,795 | $21 |
| Clarithromycin | 25 | $1,660 | $66 |
| Lamivudine | 11 | $1,566 | $142 |
| Omeprazole | 97 | $857 | $9 |
| Gavilyte-N | 40 | $800 | $20 |
| Pantoprazole | 60 | $687 | $11 |
| Peg-3350 and Electrolytes | 20 | $298 | $15 |
| Famotidine | 39 | $278 | $7 |
| Amoxicillin | 28 | $214 | $8 |
| Propranolol | 19 | $116 | $6 |
Money from drug and device companies
$583 in 2025
| 2025 | 3 | 40 | None | $583 |
| 2024 | 2 | 45 | $3,830 | $4,382 |
| 2023 | 2 | 48 | $6,000 | $6,612 |
| 2022 | 2 | 54 | $8,700 | $9,240 |
| 2021 | 4 | 63 | $5,400 | $6,298 |
| 2020 | 4 | 55 | $1,450 | $2,559 |
| 2019 | 6 | 76 | $12,810 | $15,697 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $333 | 38 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $125 | 1 payment
|
| Madrigal Pharmaceuticals | Rezdiffra | $125 | 1 payment
|
See all 40 published payments
| Gilead Sciences | Meals · 2025-12-12 | None | $7 |
| Gilead Sciences | Meals · 2025-12-05 | None | $5 |
| Gilead Sciences | Meals · 2025-11-21 | None | $8 |
| Gilead Sciences | Meals · 2025-11-14 | None | $7 |
| Gilead Sciences | Meals · 2025-11-06 | None | $7 |
| Gilead Sciences | Meals · 2025-10-31 | None | $7 |
| Gilead Sciences | Meals · 2025-10-24 | None | $7 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-22 | Entyvio | $125 |
| Gilead Sciences | Meals · 2025-10-17 | None | $7 |
| Gilead Sciences | Meals · 2025-10-10 | None | $7 |
| Gilead Sciences | Meals · 2025-10-01 | None | $16 |
| Gilead Sciences | Meals · 2025-09-12 | None | $5 |
| Gilead Sciences | Meals · 2025-08-29 | None | $8 |
| Gilead Sciences | Meals · 2025-08-15 | None | $6 |
| Gilead Sciences | Meals · 2025-08-08 | None | $7 |
| Madrigal Pharmaceuticals | Meals · 2025-08-07 | Rezdiffra | $125 |
| Gilead Sciences | Meals · 2025-08-01 | None | $17 |
| Gilead Sciences | Meals · 2025-08-01 | None | $7 |
| Gilead Sciences | Meals · 2025-07-24 | None | $5 |
| Gilead Sciences | Meals · 2025-07-11 | None | $7 |
| Gilead Sciences | Meals · 2025-06-27 | None | $9 |
| Gilead Sciences | Meals · 2025-06-20 | None | $8 |
| Gilead Sciences | Meals · 2025-06-18 | None | $30 |
| Gilead Sciences | Meals · 2025-06-06 | None | $8 |
| Gilead Sciences | Meals · 2025-05-09 | None | $9 |
| Gilead Sciences | Meals · 2025-05-02 | None | $8 |
| Gilead Sciences | Meals · 2025-04-25 | None | $6 |
| Gilead Sciences | Meals · 2025-04-18 | None | $8 |
| Gilead Sciences | Meals · 2025-04-11 | None | $8 |
| Gilead Sciences | Meals · 2025-04-04 | None | $5 |
| Gilead Sciences | Meals · 2025-03-28 | None | $7 |
| Gilead Sciences | Meals · 2025-03-21 | None | $7 |
| Gilead Sciences | Meals · 2025-03-14 | None | $6 |
| Gilead Sciences | Meals · 2025-03-07 | None | $9 |
| Gilead Sciences | Meals · 2025-02-28 | None | $7 |
| Gilead Sciences | Meals · 2025-02-03 | None | $6 |
| Gilead Sciences | Meals · 2025-01-23 | None | $28 |
| Gilead Sciences | Meals · 2025-01-23 | None | $7 |
| Gilead Sciences | Meals · 2025-01-17 | None | $7 |
| Gilead Sciences | Meals · 2025-01-10 | None | $8 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,382
| Gilead Sciences | Vemlidy | $4,258 | 44 payments
|
| Phathom Pharmaceuticals | Voquezna | $124 | 1 payment
|
2023: $6,612
| Gilead Sciences | Vemlidy | $6,591 | 47 payments
|
| Merck Sharp & Dohme | Bridion | $20 | 1 payment
|
2022: $9,240
| Gilead Sciences | Vemlidy | $9,228 | 53 payments
|
| Intercept Pharmaceuticals | Ocaliva | $12 | 1 payment
|
2021: $6,298
| Gilead Sciences | Vemlidy | $6,030 | 57 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $143 | 2 payments
|
| RedHill Biopharma | Talicia | $112 | 3 payments
|
| Celgene | Zeposia | $12 | 1 payment
|
2020: $2,559
| Gilead Sciences | Vemlidy | $2,367 | 52 payments
|
| AbbVie | Mavyret | $125 | 1 payment
|
| Braintree Laboratories | Suprep Bowel Prep | $53 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $14 | 1 payment
|
2019: $15,697
| Gilead Sciences | Vemlidy | $15,007 | 67 payments
|
| AbbVie | Mavyret | $250 | 2 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $213 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Plenvu | $108 | 2 payments
|
| Amarin Pharma | Vascepa | $100 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $19 | 1 payment
|
Professional record
- NPI
- 1427136266
- Licence
- CA G79122California G79122: Current · expires 2028-02-29
- Trained
- University of Chicago, Pritzker School of Medicine, 1992
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 2101 Forest Ave Ste 106, San Jose, CA, 95128
- NPI first listed
- 2006-11-01
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.